<!DOCTYPE html>

<html lang="fa">
<meta content="text/html;charset=utf-8" http-equiv="content-type"/>
<head><title>Erwinia asparaginase (United States and Canada: Not available): Pediatric drug information</title><link href="/d/css/bootstrap.min.css" rel="stylesheet"/><link href="/d/css/icofont.min.css" rel="stylesheet"/><link href="/d/css/classy-nav.min.css" rel="stylesheet"/><link href="/d/css/animate.css" rel="stylesheet"/><link href="/d/css/owl.carousel.css" rel="stylesheet"/><link href="/d/css/magnific-popup.css" rel="stylesheet"/><link href="/d/css/owl.theme.default.min.css" rel="stylesheet"/><link href="/d/css/style.css" rel="stylesheet"/><link href="/d/css/rtl_edited.css" rel="stylesheet"/><link href="/d/css/responsive.css" rel="stylesheet"/><link href="https://medilib.ir/uptodate_assets/main.css" rel="stylesheet">
<style>

#myUL {
  list-style-type: none;
  padding: 0;
  margin: 0;
}

#myUL li a {
  border: 1px solid #ddd;
  margin-top: -1px; /* Prevent double borders */
  background-color: #f6f6f6;
  padding: 12px;
  text-decoration: none;
  font-size: 16px;
  color: black;
  display: block
}

#myUL li a:hover:not(.header) {
  background-color: #eee;
}

#searchResult {

  list-style-type: none;
  padding: 0;
  padding-right: 20px;
}

#searchResult li a {
  border: .5px solid #ddd;
  margin-top: -1px; /* Prevent double borders */
  background-color: #79bc21;
  padding: 7px;
  text-decoration: none;
  font-size: 14px;
  color: white;
  display: block
}

#searchResult li a:hover:not(.header) {
  background-color: #222;
}


#txtHint   {
  position: absolute;
  text-shadow: none;
  width: 100%;
  margin-top: -15px;
  padding-right: 10px;

  filter: alpha(opacity=95);
  -moz-opacity: 0.95;
  opacity: 1;
  z-index: 200;
}
.countBubl {
  background:#eb0029;
  color:#fff;
  padding:5px;
  margin-top: 50%;

}
.uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > span:nth-child(1) > img:nth-child(2) {
 width: 55%;
 padding-left: 20px;
}
.uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > span:nth-child(1) > img:nth-child(3) {
 width: 20%;
}
 #Uptodate_image {
      width: 50%;
  }#uptodate-area {
      /*z-index: 99;*/
  }
#uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > div:nth-child(2) {
 margin-left: 10px;
 margin-bottom: 6%;
}
@media (max-width: @screen-xs) {
    .countBubl {
        font-size: 4px ;
    }
    #uptodate_version {
        font-size: 4px ;
    }
}

@media (max-width: @screen-sm) {
    .countBubl {
        font-size: 14px ;
    }
}
@media  all and(max-width: 820) {
    #Uptodate_image {
        width: 80% ;
    }#uptodate-area {
        z-index: 99;
    }
}@media  all and (min-width: 820) and(max-width: 88820){
    #Uptodate_image {
        width: 100% !important;
    }
    .countBubl {
        font-size: 4px ;
    }
}
div.col-md-3:nth-child(3) {
 margin-top: 6%;
}

div.col-md-3:nth-child(3) > img:nth-child(1) {
 width: 100%;
 margin-left: 11px;
}

</style>
<style media="screen" type="text/css">
  .goback {
    width: 200px;
    height: 40px;
    line-height: 40px;
    position: fixed;
    display: none;
    font-size: 15px;
    background: #71c0fa;
    z-index: 1000;
    text-align: center;
    color: #ffffff;
    -webkit-border-radius: 1px;
    -moz-border-radius: 1px;
    border-radius: 50px;
    bottom: 3.8%;
    right: 2%;
}
  .buyPackage {
  width: 100px;
  height: 100px;
  line-height: 40px;
  position: fixed;
  display: none;
  font-size: 10px;
  background: #fa759e;
  z-index: 1000;
  text-align: center;
  color: #ffffff;
  -webkit-border-radius: 1px;
  -moz-border-radius: 1px;
  border-radius: 10px;
  top: 150px;
  right: 2%;
  text-align: center;
}
.uptodate-area {
  /*background-image: url(../../assets/img/news-letter-bg.jpg);*/
  background-position: center center;
  background-size: cover;
  background-repeat: no-repeat;
    background-attachment: fixed;
  position: relative;
}
.uptodate-area::before {
  content: '';
  position: absolute;
  left: 0;
  padding-top: 100px;
  width: 100%;
}
#references{
  display: none;
}
</style>
<style>
section.sticky {
  position: sticky;
  top: 0;
  background-color: #fff !important;
  /*z-index: 100;*/
  /*padding-top: 80px;*/

}
.m4inb{
    border: solid !important;
  }

  .newsletter-area::before {
       background: unset !important;
  }
p {
    color: #555;
}
</style>

<meta content="" name="description"/>
<link href="/d/img/favicon.png" rel="icon" type="image/png"/>
</link></head>
<body>
<!-- Start Main Menu Area -->

<br/>
<br/>
<br/>
<br/>
<div class="container">
<div class="row">
</div>
</div>




<section class="teacher-area ptb-10">
<div class="container">
</div>

<section class="course-details-area ptb-60">
<div class="container">
<div class="uptodate2" style="padding:50px 0px 50px 0px;direction: ltr;text-align: left;">
<h1 style="text-align:center">Erwinia asparaginase (United States and Canada: Not available): Pediatric drug information</h1>
<div class="utdArticleSection utdStyle" id="topicContent"><div id="drugTitle">Erwinia asparaginase (United States and Canada: Not available): Pediatric drug information</div><div class="clear"></div><div id="topicText">(For additional information <a class="drug drug_general" data-topicid="17098" href="/d/html/17098.html" rel="external">see "Erwinia asparaginase (United States and Canada: Not available): Drug information"</a> and <a class="drug drug_patient" data-topicid="17099" href="/d/html/17099.html" rel="external">see "Erwinia asparaginase (United States and Canada: Not available): Patient drug information"</a>)<br/><br/>For abbreviations, symbols, and age group definitions used in Lexicomp (<a class="graphic graphic_table" href="/d/html/57469.html" rel="external">show table</a>)<div class="visuallyHidden drugH1Div" id="formulinkBodyPlaceholder"><span class="drugH1"></span></div>
<div class="list ubnlist drugH1Div drugBrandNames" id="F13388919"><span class="drugH1">Brand Names: US</span>
<ul>
<li>Erwinase [DSC];</li>
<li>Erwinaze [DSC]</li></ul></div>
<div class="list canbnlist drugH1Div drugBrandNames" id="F55773693"><span class="drugH1">Brand Names: Canada</span>
<ul>
<li>Erwinase [DSC]</li></ul></div>
<div class="list_set htclist drugH1Div drugBrandNames" id="F13486876"><span class="drugH1">Therapeutic Category</span>
<ul>
<li>
<span class="list-set-name">Antineoplastic Agent, Enzyme</span>;</li>
<li>
<span class="list-set-name">Antineoplastic Agent, Miscellaneous</span></li></ul></div>
<div class="block dop drugH1Div" id="F13389044"><span class="drugH1">Dosing: Pediatric</span>
<p style="text-indent:0em;display:inline">
<b>Note:</b> Erwinaze has been discontinued in the United States for &gt;1 year. If administering IV, consider monitoring nadir serum asparaginase activity (NSAA) levels; if desired levels are not achieved, change to IM administration. Antiemetics may be recommended to prevent nausea and vomiting; in pediatrics, IV doses ≥20,000 units/m<sup>2</sup> are associated with a high emetic potential (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-30729654']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-30729654'])">Ref</a></span>).</p>
<div class="collapsible-indication">
<span class="collapsible-indication-title" data-indication-id="3b5fd58c-2ade-43ce-a3f5-be85a60e433f">Acute lymphoblastic leukemia</span>
<div class="collapsible-indication-wrap">
<p style="text-indent:-2em;margin-left:2em;">
<b>Acute lymphoblastic leukemia:</b></p>
<p style="text-indent:-2em;margin-left:4em;">
<b>Acute lymphoblastic leukemia: </b>Children and Adolescents:</p>
<p style="text-indent:-2em;margin-left:6em;">
<i>As a substitute for pegaspargase:</i> IM, IV: 25,000 units/m<sup>2</sup>/dose 3 times weekly (Mon, Wed, Fri) for 6 doses for each planned pegaspargase dose</p>
<p style="text-indent:-2em;margin-left:6em;">
<i>As a substitute for asparaginase (E. coli):</i> IM, IV: 25,000 units/m<sup>2</sup>/dose for each scheduled asparaginase (<i>E. coli</i>) dose</p>
<p style="text-indent:-2em;margin-left:4em;">
<b>Acute lymphoblastic leukemia: </b>
<i>Canadian labeling:</i> Infants, Children, and Adolescents &lt;14 years: IM: 6,000 units/m<sup>2</sup> 3 times weekly for 9 doses beginning day 4 of week 1 (in combination with allopurinol, vincristine, prednisone, methotrexate, and daunorubicin)</p></div>
</div>
<p style="text-indent:-2em;margin-left:2em;">
<b>Dosage adjustment for toxicity:</b></p>
<p style="text-indent:-2em;margin-left:4em;">Manufacturer's labeling: Children and Adolescents:</p>
<p style="text-indent:-2em;margin-left:6em;">
<i>Hemorrhagic or thrombotic event:</i> Discontinue treatment; may resume treatment upon symptom resolution.</p>
<p style="text-indent:-2em;margin-left:6em;">
<i>Pancreatitis:</i></p>
<p style="text-indent:-2em;margin-left:8em;">Mild pancreatitis: Withhold treatment until signs and symptoms subside and amylase returns to normal; may resume after resolution.</p>
<p style="text-indent:-2em;margin-left:8em;">Severe or hemorrhagic pancreatitis (abdominal pain &gt;72 hours and amylase ≥2 x ULN): Discontinue treatment; further use is contraindicated.</p>
<p style="text-indent:-2em;margin-left:6em;">
<i>Serious hypersensitivity:</i> Discontinue treatment.</p>
<p style="text-indent:-2em;margin-left:4em;">The following adjustments have also been recommended for asparaginase products (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-21827361']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-21827361'])">Ref</a></span>): Older Adolescents:</p>
<p style="text-indent:-2em;margin-left:6em;">
<i>Hyperammonemia-related fatigue:</i> Continue therapy for grade 2 toxicity. If grade 3 toxicity occurs, reduce dose by 25%; resume full dose when toxicity ≤ grade 2 (make up for missed doses). If grade 4 toxicity occurs, reduce dose by 50%; resume full dose when toxicity ≤ grade 2 (make up for missed doses).</p>
<p style="text-indent:-2em;margin-left:6em;">
<i>Hyperglycemia:</i> Continue therapy for uncomplicated hyperglycemia. If hyperglycemia requires insulin therapy, hold asparaginase (and any concomitant corticosteroids) until blood glucose controlled; resume dosing at prior dose level. For life-threatening hyperglycemia or toxicity requiring urgent intervention, hold asparaginase (and corticosteroids) until blood glucose is controlled with insulin; resume asparaginase and do not make up for missed doses.</p>
<p style="text-indent:-2em;margin-left:6em;">
<i>Hypersensitivity reactions:</i> May continue dosing for urticaria without bronchospasm, hypotension, edema, or need for parenteral intervention. If wheezing or other symptomatic bronchospasm with or without urticaria, angioedema, hypotension, and/or life-threatening hypersensitivity reactions occur, discontinue asparaginase.</p>
<p style="text-indent:-2em;margin-left:6em;">
<i>Hypertriglyceridemia:</i> If serum triglyceride level &lt;1,000 mg/dL, continue asparaginase but monitor closely for pancreatitis. If triglyceride level &gt;1,000 mg/dL, hold asparaginase and monitor; resume therapy at prior dose level after triglyceride level returns to baseline.</p>
<p style="text-indent:-2em;margin-left:6em;">
<i>Pancreatitis:</i></p>
<p style="text-indent:-2em;margin-left:8em;">Asymptomatic amylase or lipase &gt;3 times ULN (chemical pancreatitis) or radiologic abnormalities only: Continue asparaginase and monitor levels closely.</p>
<p style="text-indent:-2em;margin-left:8em;">Symptomatic amylase or lipase &gt;3 times ULN: Hold asparaginase until enzyme levels stabilize or are declining.</p>
<p style="text-indent:-2em;margin-left:8em;">Symptomatic pancreatitis or clinical pancreatitis (abdominal pain with amylase or lipase &gt;3 times ULN for &gt;3 days and/or development of pancreatic pseudocyst): Permanently discontinue asparaginase.</p>
<p style="text-indent:-2em;margin-left:6em;">
<i>Thrombosis and bleeding, CNS:</i></p>
<p style="text-indent:-2em;margin-left:8em;">Thrombosis: Continue therapy for abnormal laboratory findings without a clinical correlate. If grade 3 toxicity occurs, discontinue therapy; if CNS signs/symptoms are fully resolved and further asparaginase doses are required, may resume therapy at a lower dose and/or longer intervals between doses. Discontinue therapy for grade 4 toxicity.</p>
<p style="text-indent:-2em;margin-left:8em;">Hemorrhage: Discontinue therapy; do not withhold therapy for abnormal laboratory findings without a clinical correlate. If grade 3 toxicity occurs, discontinue therapy; if CNS signs/symptoms are fully resolved and further asparaginase doses are required, may resume therapy at a lower dose and/or longer intervals between doses. Discontinue therapy for grade 4 toxicity.</p>
<p style="text-indent:-2em;margin-left:6em;">
<i>Thrombosis and bleeding, non-CNS:</i></p>
<p style="text-indent:-2em;margin-left:8em;">Thrombosis: Continue therapy for abnormal laboratory findings without a clinical correlate. If grade 3 or 4 toxicity occurs, withhold therapy until acute toxicity and clinical signs resolve and anticoagulant therapy is stable or completed. Do not withhold therapy for abnormal laboratory findings without clinical correlate.</p>
<p style="text-indent:-2em;margin-left:8em;">Hemorrhage: If grade 2 bleeding in conjunction with hypofibrinogenemia occurs, withhold therapy until bleeding ≤ grade 1. Do not withhold therapy for abnormal laboratory findings without clinical correlate. For grade 3 or 4 bleeding, withhold therapy until bleeding ≤ grade 1 and until acute toxicity and clinical signs resolve and coagulant replacement therapy is stable or completed.</p></div>
<div class="block dorp drugH1Div" id="F51065045"><span class="drugH1">Dosing: Kidney Impairment: Pediatric</span>
<p style="text-indent:0em;display:inline">All patients: There are no dosage adjustments provided in the manufacturer's labeling.</p></div>
<div class="block dohp drugH1Div" id="F51065046"><span class="drugH1">Dosing: Hepatic Impairment: Pediatric</span>
<p style="text-indent:-2em;margin-left:2em;">There are no dosage adjustments provided in the manufacturer's labeling; however, the following adjustments have been recommended for other asparaginase products for hepatotoxicity during treatment (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-21827361']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-21827361'])">Ref</a></span>):</p>
<p style="text-indent:-2em;margin-left:4em;">Older Adolescents:</p>
<p style="text-indent:-2em;margin-left:6em;">ALT/AST &gt;3 to 5 times ULN: Continue therapy.</p>
<p style="text-indent:-2em;margin-left:6em;">ALT/AST &gt;5 to 20 times ULN: Delay next dose until transaminases &lt;3 times ULN.</p>
<p style="text-indent:-2em;margin-left:6em;">ALT/AST &gt;20 times ULN: Discontinue therapy if takes longer than 1 week for transaminases to return to &lt;3 times ULN.</p>
<p style="text-indent:-2em;margin-left:6em;">Direct bilirubin &lt;3 mg/dL: Continue therapy.</p>
<p style="text-indent:-2em;margin-left:6em;">Direct bilirubin 3.1 to 5 mg/dL: Hold asparaginase and resume when direct bilirubin &lt;2 mg/dL; consider switching to alternate asparaginase product.</p>
<p style="text-indent:-2em;margin-left:6em;">Direct bilirubin &gt;5 mg/dL: Discontinue asparaginase; do not substitute other asparaginase products; do not make up for missed doses.</p></div>
<div class="block doa drugH1Div" id="F13389045"><span class="drugH1">Dosing: Adult</span><p>(For additional information <a class="drug drug_general" data-topicid="17098" href="/d/html/17098.html" rel="external">see "Erwinia asparaginase (United States and Canada: Not available): Drug information"</a>)</p>
<p style="text-indent:-2em;margin-left:2em;">
<b>Note:</b> Erwinaze has been discontinued in the United States for &gt;1 year.</p>
<p style="text-indent:-2em;margin-left:2em;">
<b>Note:</b> Do not substitute asparaginase (<i>Erwinia)</i> for asparaginase (<i>Erwinia </i>[Recombinant]), or vice versa; the products are different and dosing differs. Consider thromboprophylaxis with low-molecular-weight heparin (LMWH) during induction and intensification phases of asparaginase therapy, particularly in patients at high risk for venous thromboembolism; withhold LMWH for platelet count &lt;30,000/mm<sup>3</sup> (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-31999063']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-31999063'])">Ref</a></span>). If administering asparaginase (<i>Erwinia</i>) IV, consider monitoring nadir serum asparaginase activity (NSAA) levels; if desired levels are not achieved, change to IM administration.</p>
<div class="collapsible-indication">
<span class="collapsible-indication-title" data-indication-id="3b5fd58c-2ade-43ce-a3f5-be85a60e433f">Acute lymphoblastic leukemia</span>
<div class="collapsible-indication-wrap">
<p style="text-indent:-2em;margin-left:2em;">
<b>Acute lymphoblastic leukemia: </b></p>
<p style="text-indent:-2em;margin-left:4em;">
<i>As a substitute for pegaspargase:</i>
<b>IM, IV:</b> 25,000 units/m<sup>2</sup> 3 times weekly (Mon, Wed, Fri) for 6 doses for each planned pegaspargase dose.</p>
<p style="text-indent:-2em;margin-left:4em;">
<i>As a substitute for asparaginase (E. coli):</i>
<b>IM, IV:</b> 25,000 units/m<sup>2</sup> for each scheduled asparaginase (<i>E. coli</i>) dose.</p></div>
</div>
</div>
<div class="block dora drugH1Div" id="F50989978"><span class="drugH1">Dosing: Kidney Impairment: Adult</span>
<p style="text-indent:0em;display:inline">There are no dosage adjustments provided in the manufacturer's labeling.</p></div>
<div class="block doha drugH1Div" id="F50987318"><span class="drugH1">Dosing: Hepatic Impairment: Adult</span>
<p style="text-indent:0em;display:inline">There are no dosage adjustments provided in the manufacturer's labeling; however, the following adjustments have been recommended for other asparaginase products for hepatotoxicity during treatment (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-21827361']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-21827361'])">Ref</a></span>):</p>
<p style="text-indent:-2em;margin-left:2em;">ALT/AST &gt;3 to 5 times ULN: Continue therapy.</p>
<p style="text-indent:-2em;margin-left:2em;">ALT/AST &gt;5 to 20 times ULN: Delay next dose until transaminases &lt;3 times ULN.</p>
<p style="text-indent:-2em;margin-left:2em;">ALT/AST &gt;20 times ULN: Discontinue therapy if takes longer than 1 week for transaminases to return to &lt;3 times ULN.</p>
<p style="text-indent:-2em;margin-left:2em;">Direct bilirubin &lt;3 mg/dL: Continue therapy.</p>
<p style="text-indent:-2em;margin-left:2em;">Direct bilirubin 3.1 to 5 mg/dL: Hold asparaginase and resume when direct bilirubin &lt;2 mg/dL; consider switching to alternate asparaginase product.</p>
<p style="text-indent:-2em;margin-left:2em;">Direct bilirubin &gt;5 mg/dL: Discontinue asparaginase; do not substitute other asparaginase products; do not make up for missed doses.</p></div>
<div class="block adr drugH1Div" id="F13389029"><span class="drugH1">Adverse Reactions</span>
<p style="text-indent:0em;display:inline">The following adverse drug reactions and incidences are derived from product labeling unless otherwise specified.</p>
<p style="text-indent:-2em;margin-left:2em;">&gt;10%:</p>
<p style="text-indent:-2em;margin-left:4em;">Endocrine &amp; metabolic: Hyperglycemia</p>
<p style="text-indent:-2em;margin-left:4em;">Gastrointestinal: Nausea, vomiting</p>
<p style="text-indent:-2em;margin-left:4em;">Hepatic: Increased serum transaminases</p>
<p style="text-indent:-2em;margin-left:4em;">Hypersensitivity: Hypersensitivity reaction</p>
<p style="text-indent:-2em;margin-left:4em;">Immunologic: Antibody development</p>
<p style="text-indent:-2em;margin-left:2em;">1% to 10%:</p>
<p style="text-indent:-2em;margin-left:4em;">Cardiovascular: Thrombosis</p>
<p style="text-indent:-2em;margin-left:4em;">Endocrine &amp; metabolic: Decreased glucose tolerance</p>
<p style="text-indent:-2em;margin-left:4em;">Gastrointestinal: Abdominal distress, abdominal pain, diarrhea, pancreatitis, stomatitis</p>
<p style="text-indent:-2em;margin-left:4em;">Hematologic &amp; oncologic: Hemorrhage</p>
<p style="text-indent:-2em;margin-left:4em;">Hepatic: Hyperbilirubinemia</p>
<p style="text-indent:-2em;margin-left:4em;">Hypersensitivity: Local hypersensitivity reaction</p>
<p style="text-indent:-2em;margin-left:4em;">Miscellaneous: Fever</p>
<p style="text-indent:-2em;margin-left:2em;">&lt;1%: Anaphylaxis, hyperammonemia</p>
<p style="text-indent:-2em;margin-left:2em;">Frequency not defined: Cardiovascular: Cerebrovascular accident</p>
<p style="text-indent:-2em;margin-left:2em;">Postmarketing: Pulmonary embolism, sagittal sinus thrombosis</p></div>
<div class="block coi drugH1Div" id="F13389026"><span class="drugH1">Contraindications</span>
<p style="text-indent:-2em;margin-left:2em;">History of serious hypersensitivity reactions, including anaphylaxis to asparaginase (<i>Erwinia</i>) or any component of the formulation; history of serious pancreatitis, serious thrombosis, or serious hemorrhagic events with prior asparaginase treatment.</p>
<p style="text-indent:-2em;margin-left:2em;">
<i>Canadian labeling:</i> Additional contraindications (not in the US labeling): Patients who are or could become pregnant.</p></div>
<div class="block war drugH1Div" id="F13389027"><span class="drugH1">Warnings/Precautions</span>
<p style="text-indent:-2em;margin-left:2em;">
<b>
<i>Concerns related to adverse effects:</i></b></p>
<p style="text-indent:-2em;margin-left:4em;">• Glucose intolerance: In clinical trials, 5% of patients experienced glucose intolerance; may be irreversible.</p>
<p style="text-indent:-2em;margin-left:4em;">• Hypersensitivity reactions: Serious hypersensitivity reactions (grade 3 and 4), including anaphylaxis, have occurred in 5% of patients in clinical trials.</p>
<p style="text-indent:-2em;margin-left:4em;">• Pancreatitis: Pancreatitis has been reported in 4% of patients in clinical trials.</p>
<p style="text-indent:-2em;margin-left:4em;">• Thrombosis and hemorrhage: Serious thrombotic events, including sagittal sinus thrombosis and pulmonary embolism, have been reported with asparaginase formulations. Decreases in fibrinogen, protein C activity, protein S activity, and antithrombin III have been noted following a 2-week treatment course administered intramuscularly.</p>
<p style="text-indent:-2em;margin-left:2em;">
<b>
<i>Other warnings/precautions:</i></b></p>
<p style="text-indent:-2em;margin-left:4em;">• Medication error prevention: Do not interchange asparaginase (<i>Erwinia)</i> for asparaginase (<i>Erwinia </i>[Recombinant]), asparaginase (<i>Escherichia coli)</i>, calaspargase pegol, or pegaspargase; ensure the proper formulation, route of administration, and dose prior to administration.</p></div>
<div class="block prod-avail drugH1Div" id="F57263999"><span class="drugH1">Product Availability</span>
<p style="text-indent:0em;display:inline">Erwinaze has been discontinued in the United States for &gt;1 year.</p></div>
<div class="block foc drugH1Div" id="F13388920"><span class="drugH1">Dosage Forms: US</span>
<p style="text-indent:0em;text-align:justify;display:inline">Excipient information presented when available (limited, particularly for generics); consult specific product labeling.  [DSC] = Discontinued product</p>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">Solution Reconstituted, Injection: </p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">Erwinase: 10,000 units (1 ea [DSC])</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">Erwinaze: 10,000 units (1 ea [DSC])</p></div>
<div class="block geq drugH1Div" id="F13389021"><span class="drugH1">Generic Equivalent Available: US</span>
<p style="text-indent:0em;display:inline">No</p></div>
<div class="block fee drugH1Div" id="F16322923"><span class="drugH1">Pricing: US</span>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">
<b>Solution (reconstituted)</b> (Erwinase Injection)</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">10000 unit (per each): $4,837.01</p>
<p style="text-indent:0em;">
<b>Disclaimer: </b>A representative AWP (Average Wholesale Price) price or price range is provided as reference price only. A range is provided when more than one manufacturer's AWP price is available and uses the low and high price reported by the manufacturers to determine the range. The pricing data should be used for benchmarking purposes only, and as such should not be used alone to set or adjudicate any prices for reimbursement or purchasing functions or considered to be an exact price for a single product and/or manufacturer.  Medi-Span expressly disclaims all warranties of any kind or nature, whether express or implied, and assumes no liability with respect to accuracy of price or price range data published in its solutions.  In no event shall Medi-Span be liable for special, indirect, incidental, or consequential damages arising from use of price or price range data.  Pricing data is updated monthly.</p></div>
<div class="block dinfoc drugH1Div" id="F55773694"><span class="drugH1">Dosage Forms: Canada</span>
<p style="text-indent:0em;text-align:justify;display:inline">Excipient information presented when available (limited, particularly for generics); consult specific product labeling.  [DSC] = Discontinued product</p>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">Solution Reconstituted, Injection: </p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">Erwinase: 10,000 units ([DSC])</p></div>
<div class="block admp drugH1Div" id="F52614506"><span class="drugH1">Administration: Pediatric</span>
<p style="text-indent:0em;display:inline">Parenteral:<b> Note:</b> Vials from certain batches should <b>only</b> be administered intramuscularly or require the use of a 0.2-micron filter if administered intravenously.</p>
<p style="text-indent:-2em;margin-left:2em;">IM: The volume of each single injection site should be limited to 2 mL; use multiple injection sites for volumes &gt;2 mL.</p>
<p style="text-indent:-2em;margin-left:2em;">IV: Infuse over 1 or 2 hours; do not infuse other medications through the same IV line; some product lots may require use of a 0.2-micron filter; refer to manufacturer for batch-specific information. <b>Note</b>: Some product lots <b>not</b> for IV administration; refer to manufacturer for batch-specific information.</p>
<p style="text-indent:-2em;margin-left:2em;">Antiemetics may be recommended to prevent nausea and vomiting; in pediatrics, IV doses ≥20,000 units/m<sup>2</sup> are associated with a high emetic potential (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-30729654']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-30729654'])">Ref</a></span>).</p></div>
<div class="block adm drugH1Div" id="F13389050"><span class="drugH1">Administration: Adult</span>
<p style="text-indent:-2em;margin-left:2em;">
<b>IM:</b> The volume of each single injection site should be limited to 2 mL; use multiple injections for volumes &gt;2 mL.</p>
<p style="text-indent:-2em;margin-left:2em;">
<b>IV:</b> Infuse over 1 to 2 hours; do not infuse other medications through the same IV line.</p>
<p style="text-indent:-2em;margin-left:2em;">Asparaginase (<i>Erwinia</i>) should be administered in a setting with resuscitation equipment and agents necessary to manage anaphylaxis.</p></div>
<div class="block sts drugH1Div" id="F13389035"><span class="drugH1">Storage/Stability</span>
<p style="text-indent:0em;display:inline">Store intact vials refrigerated at 2°C to 8°C (36°F to 46°F). Protect from light. Within 15 minutes of reconstitution, withdraw appropriate volume for dose into a polypropylene syringe. Do not freeze or refrigerate reconstituted solution; discard if not administered within 4 hours.</p></div>
<div class="block usep drugH1Div" id="F53570984"><span class="drugH1">Use</span>
<p style="text-indent:0em;display:inline">Treatment (in combination with other chemotherapy agents) of acute lymphoblastic leukemia (ALL) in patients with hypersensitivity to <i>E. coli</i>-derived asparaginase (FDA approved in ages ≥1 year and adults)</p></div>
<div class="block mst drugH1Div" id="F13381921"><span class="drugH1">Medication Safety Issues</span>
<div class="collapsible">
<span class="collapsible-title">Sound-alike/look-alike issues:</span>
<div class="collapsible-wrap">
<p style="text-indent:-2em;margin-left:4em;">Asparaginase <i>(Erwinia)</i> may be confused with asparaginase (<i>Erwinia </i>[Recombinant]), asparaginase <i>(Escherichia coli)</i>, calaspargase pegol, pegaspargase.</p>
<p style="text-indent:-2em;margin-left:4em;">Erwinaze may be confused with Asparlas, Elaprase, Elspar, Oncaspar, Rylaze.</p></div>
</div>
<div class="collapsible">
<span class="collapsible-title">High alert medication:</span>
<div class="collapsible-wrap">
<p style="text-indent:-2em;margin-left:4em;">This medication is in a class the Institute for Safe Medication Practices (ISMP) includes among its list of drug classes which have a heightened risk of causing significant patient harm when used in error.</p></div>
</div>
<div class="collapsible">
<span class="collapsible-title">Other safety concerns:</span>
<div class="collapsible-wrap">
<p style="text-indent:-2em;margin-left:4em;">Asparaginase is available as asparaginase (<i>Erwinia</i>), asparaginase (<i>Erwinia</i> [Recombinant]), and asparaginase (<i>Escherichia coli</i>). Use caution when selecting the asparaginase formulation, as dosing and administration vary between the products.</p></div>
</div>
</div>
<div class="block cyt drugH1Div" id="F13460902"><span class="drugH1">Metabolism/Transport Effects</span>
<p style="text-indent:0em;display:inline">None known.</p></div>
<div class="block dri drugH1Div" id="F13460900"><span class="drugH1">Drug Interactions</span><br/><br/><div class="clear"></div><p xmlns=""></p><div class="inner" xmlns=""><p style="text-indent:0em;display:inline"><b>Note</b>: Interacting drugs may <b>not be individually listed below</b> if they are part of a group interaction (eg, individual drugs within “CYP3A4 Inducers [Strong]” are NOT listed).  For a complete list of drug interactions by individual drug name and detailed management recommendations, use the Lexicomp drug interactions program by clicking on the “Launch drug interactions program” link above.</p><p xmlns=""></p></div>
<p style="text-indent:-2em;margin-left:2em;">Hormonal Contraceptives: May enhance the thrombogenic effect of Asparaginase Products. Management: Consider discontinuing hormonal contraceptives and using an alternative contraceptive method in patients treated with asparaginase products.<i> Risk D: Consider therapy modification</i></p></div>
<div class="block rep_considerations drugH1Div" id="F54020736"><span class="drugH1">Reproductive Considerations</span>
<p style="text-indent:0em;display:inline">Evaluate pregnancy status prior to use in patients who could become pregnant. Patients who could become pregnant should use effective contraception during therapy and for 3 months after the last dose of asparaginase (<i>Erwinia</i>); use of oral contraceptives is not recommended.</p></div>
<div class="block pri drugH1Div" id="F13389023"><span class="drugH1">Pregnancy Considerations</span>
<p style="text-indent:0em;">Based on data from animal reproduction studies, in utero exposure to asparaginase (<i>Erwinia</i>) may cause fetal harm.</p></div>
<div class="block mopp drugH1Div" id="F53570985"><span class="drugH1">Monitoring Parameters</span>
<p style="text-indent:0em;display:inline">CBC with differential, amylase, liver enzymes, blood glucose (baseline and periodically during treatment), coagulation parameters, for IV administration, consider monitoring nadir serum asparaginase activity (NSAA) levels. Monitor for symptoms of hypersensitivity; symptoms of pancreatitis, thrombosis, or hemorrhage </p></div>
<div class="block pha drugH1Div" id="F13389037"><span class="drugH1">Mechanism of Action</span>
<p style="text-indent:0em;display:inline">Asparaginase catalyzes the deamidation of asparagine to aspartic acid and ammonia, reducing circulating levels of asparagine. Leukemia cells lack asparagine synthetase and are unable to synthesize asparagine. Asparaginase reduces the exogenous asparagine source for the leukemic cells, resulting in cytotoxicity specific to leukemic cells.</p></div>
<div class="block phk drugH1Div" id="F13389039"><span class="drugH1">Pharmacokinetics (Adult Data Unless Noted)</span>
<p style="text-indent:0em;display:inline">Half-life elimination: IM: ~16 hours (Asselin 1993; Avramis 2005); IV: ~7.5 hours</p></div>
</div><div class="headingAnchor" id="references"><ol id="reference">
<li>
<div class="reference" id="lexi-content-ref-8355045">
<a name="8355045"></a>Asselin BL, Whitin JC, Cappola DJ, et al. Comparative Pharmacokinetic Studies of Three Asparaginase Preparations. <i>J Clin Oncol</i>. 1993;11(9):1780-1786.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/erwinia-asparaginase-united-states-and-canada-not-available-pediatric-drug-information/abstract-text/8355045/pubmed" id="8355045" target="_blank">8355045</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-15828851">
<a name="15828851"></a>Avramis VI, Panosyan EH. Pharmacokinetic/Pharmacodynamic Relationships of Asparaginase Formulations: The Past, the Present and Recommendations for the Future. <i>Clin Pharmacokinet</i>. 2005;44(4):367-393.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/erwinia-asparaginase-united-states-and-canada-not-available-pediatric-drug-information/abstract-text/15828851/pubmed" id="15828851" target="_blank">15828851</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-21368672">
<a name="21368672"></a>Cheung KC, van den Bemt PM, Torringa ML, et al. Erroneous Exchange of Asparaginase Forms in the Treatment of Acute Lymphoblastic Leukemia. <i>J Pediatr Hematol Oncol</i>. 2011;33(3):e109-e113.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/erwinia-asparaginase-united-states-and-canada-not-available-pediatric-drug-information/abstract-text/21368672/pubmed" id="21368672" target="_blank">21368672</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-Duval.1">
<a name="Duval.1"></a>Duval M, Suciu S, Ferster A, et al. Comparison of <i>Escherichia Coli </i>-Asparaginase With <i>Erwinia</i>-Asparaginase in the Treatment of Childhood Lymphoid Malignancies: Results of a Randomized European Organisation for Research and Treatment of Cancer − Children's Leukemia Group Phase 3 Trial. <i>Blood</i>. 2002;99(8):2734-2739.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-Jazz.1">
<a name="Jazz.1"></a>Erwinaze (asparaginase) [prescribing information]. Palo Alto, CA: Jazz Pharmaceuticals; December 2019.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-Jazz.2">
<a name="Jazz.2"></a>Erwinase (asparaginase) [Canadian product monograph]. Lyon, France: Jazz Pharmaceuticals France SAS; August 2016.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-Frey.1">
<a name="Frey.1"></a>Frey N. Dear Health Care Professional letter (Erwinaze Batch 178K). Palo Alto, CA: Jazz Pharmaceuticals Inc; October 15, 2016.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-21210774">
<a name="21210774"></a>Grace RF, Dahlberg SE, Neuberg D, et al. The Frequency and Management of Asparaginase-Related Thrombosis in Paediatric and Adult Patients With Acute Lymphoblastic Leukaemia Treated on Dana-Farber Cancer Institute Consortium Protocols. <i>Br J Haematol</i>. 2011;152(4):452-459.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/erwinia-asparaginase-united-states-and-canada-not-available-pediatric-drug-information/abstract-text/21210774/pubmed" id="21210774" target="_blank">21210774</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-33939491">
<a name="33939491"></a>Griggs JJ, Bohlke K, Balaban EP, et al. Appropriate systemic therapy dosing for obese adult patients with cancer: ASCO guideline update.<i> J Clin Oncol.</i> 2021;39(18):2037-2048. doi:10.1200/JCO.21.00471<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/erwinia-asparaginase-united-states-and-canada-not-available-pediatric-drug-information/abstract-text/33939491/pubmed" id="33939491" target="_blank">33939491</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-32716741">
<a name="32716741"></a>Hwang JP, Feld JJ, Hammond SP, et al. Hepatitis B virus screening and management for patients with cancer prior to therapy: ASCO provisional clinical opinion update. <i>J Clin Oncol</i>. 2020;38(31):3698-3715. doi:10.1200/JCO.20.01757<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/erwinia-asparaginase-united-states-and-canada-not-available-pediatric-drug-information/abstract-text/32716741/pubmed" id="32716741" target="_blank">32716741</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-30729654">
<a name="30729654"></a>Paw Cho Sing E, Robinson PD, Flank J, et al. Classification of the acute emetogenicity of chemotherapy in pediatric patients: A clinical practice guideline. <i>Pediatr Blood Cancer</i>. 2019;66(5):e27646. doi:10.1002/pbc.27646<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/erwinia-asparaginase-united-states-and-canada-not-available-pediatric-drug-information/abstract-text/30729654/pubmed" id="30729654" target="_blank">30729654</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-Salzer.1">
<a name="Salzer.1"></a>Salzer W, Asselin B, Supko JG, et al. Administration of Erwinia Asparaginase (Erwinase®) Following Allergy to PEG-Asparaginase In Children and Young Adults With Acute Lymphoblastic Leukemia Treated on AALL07P2 Achieves Therapeutic Nadir Serum Asparaginase Activity: A Report From the Children's Oncology Group (COG). <i>Blood</i>. 2010;116(21):2134 [abstract 2134 from 2010 ASH Annual Meeting].</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-23741010">
<a name="23741010"></a>Salzer WL, Asselin B, Supko JG, et al. Erwinia asparaginase achieves therapeutic activity after pegaspargase allergy: a report from the Children’s Oncology Group. <i>Blood</i>. 2013;122(4):507-514.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/erwinia-asparaginase-united-states-and-canada-not-available-pediatric-drug-information/abstract-text/23741010/pubmed" id="23741010" target="_blank">23741010</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-21337682">
<a name="21337682"></a>Schrey D, Speitel K, Lanvers-Kaminsky C, et al. Five-Year Single-Center Study of Asparaginase Therapy Within the ALL-BFM 2000 Trial. <i>Pediatr Blood Cancer</i>. 2011;57(3):378-384.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/erwinia-asparaginase-united-states-and-canada-not-available-pediatric-drug-information/abstract-text/21337682/pubmed" id="21337682" target="_blank">21337682</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-32395867">
<a name="32395867"></a>Sibai H, Chen R, Liu X, et al. Anticoagulation prophylaxis reduces venous thromboembolism rate in adult acute lymphoblastic leukaemia treated with asparaginase-based therapy. <i>Br J Haematol</i>. Published online May 12, 2020. doi:10.1111/bjh.16695<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/erwinia-asparaginase-united-states-and-canada-not-available-pediatric-drug-information/abstract-text/32395867/pubmed" id="32395867" target="_blank">32395867</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-21827361">
<a name="21827361"></a>Stock W, Douer D, DeAngelo DJ, et al. Prevention and management of asparaginase/pegasparaginase-associated toxicities in adults and older adolescents: recommendations of an expert panel. <i>Leuk Lymphoma</i>. 2011;52(12):2237-2253.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/erwinia-asparaginase-united-states-and-canada-not-available-pediatric-drug-information/abstract-text/21827361/pubmed" id="21827361" target="_blank">21827361</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-19672973">
<a name="19672973"></a>Vrooman LM, Supko JG, Neuberg DS, et al. <i>Erwinia</i> Asparaginase After Allergy to <i>E. coli</i> Asparaginase in Children With Acute Lymphoblastic Leukemia. <i>Pediatr Blood Cancer</i>. 2010;54(2):199-205.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/erwinia-asparaginase-united-states-and-canada-not-available-pediatric-drug-information/abstract-text/19672973/pubmed" id="19672973" target="_blank">19672973</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-18421047">
<a name="18421047"></a>Yang L, Panetta JC, Cai X, et al. Asparaginase may influence dexamethasone pharmacokinetics in acute lymphoblastic leukemia. <i>J Clin Oncol</i>. 2008;26(12):1932-1939.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/erwinia-asparaginase-united-states-and-canada-not-available-pediatric-drug-information/abstract-text/18421047/pubmed" id="18421047" target="_blank">18421047</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-19184328">
<a name="19184328"></a>Zalewska-Szewczyk B, Gach A, Wyka K, et al. The cross-reactivity of anti-Asparaginase antibodies against different L-Asparaginase preparations. <i>Clin Exp Med</i>. 2009;9(2):113-116.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/erwinia-asparaginase-united-states-and-canada-not-available-pediatric-drug-information/abstract-text/19184328/pubmed" id="19184328" target="_blank">19184328</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-31999063">
<a name="31999063"></a>Zwicker JI, Wang TF, DeAngelo DJ, et al. The prevention and management of asparaginase-related venous thromboembolism in adults: guidance from the SSC on hemostasis and malignancy of the ISTH. <i>J Thromb Haemost</i>. 2020;18(2):278-284. doi:10.1111/jth.14671<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/erwinia-asparaginase-united-states-and-canada-not-available-pediatric-drug-information/abstract-text/31999063/pubmed" id="31999063" target="_blank">31999063</a>]</span>
</div>
</li></ol></div><div id="topicVersionRevision">Topic 89192 Version 142.0</div></div>
</div>
</div>

</section>

</section>
<!-- End Main Menu Area -->
<!-- Start Search Popup Area -->


<!-- End Footer Area -->
<!-- Back to top -->

<a class="scrolltop" href="#top"><i class="icofont-hand-drawn-up"></i></a>
<!-- End Back to top -->
<!-- jQuery Min JS -->

<!-- Prpper JS -->

<!-- Bootstrap Min JS -->

<!-- Classy Nav Min Js -->

<!-- Owl Carousel Min Js -->

<!-- Magnific Popup JS -->

<!-- CounterUp JS -->

<!-- Waypoints JS -->

<!-- Form Validator Min JS -->

<!-- Contact Form Min JS -->

<!-- Main JS -->

<!-- Global site tag (gtag.js) - Google Analytics -->






</body>
</html>
